We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.50 | 0.98% | 1,599.00 | 1,599.50 | 1,600.50 | 1,600.00 | 1,575.00 | 1,579.50 | 5,149,016 | 16:35:14 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.37 | 65.87B |
From Apr 2019 to Apr 2024
L'action GlaxoSmithKline (GSK.LN) perd 1,3%, à 13,42 livres sterling, car le marché pense que Pfizer et Allergan confirmeront leur projet de fusion pour un montant de 150 milliards de dollars. Dans cette hypothèse, le laboratoire pharmaceutique britannique ne constituerait alors plus une cible potentielle pour Pfizer. Glaxo aurait rejeté les approches du géant américain, qui aurait ensuite entamé des discussions avec Allergan.
-Denise Roland, Dow Jones Newswires (Version française Aurélie Henri) ed: VLV
(END) Dow Jones Newswires
November 23, 2015 05:04 ET (10:04 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
